For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Gilead Sciences (GILD - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Gilead Sciences is a member of the Medical sector. This group includes 844 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. GILD is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for GILD's full-year earnings has moved 5.97% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, GILD has moved about 5.63% on a year-to-date basis. In comparison, Medical companies have returned an average of 3.85%. This shows that Gilead Sciences is outperforming its peers so far this year.
To break things down more, GILD belongs to the Medical - Biomedical and Genetics industry, a group that includes 352 individual companies and currently sits at #64 in the Zacks Industry Rank. This group has gained an average of 3.46% so far this year, so GILD is performing better in this area.
Investors with an interest in Medical stocks should continue to track GILD. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Gilead Sciences (GILD - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Gilead Sciences is a member of the Medical sector. This group includes 844 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. GILD is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for GILD's full-year earnings has moved 5.97% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, GILD has moved about 5.63% on a year-to-date basis. In comparison, Medical companies have returned an average of 3.85%. This shows that Gilead Sciences is outperforming its peers so far this year.
To break things down more, GILD belongs to the Medical - Biomedical and Genetics industry, a group that includes 352 individual companies and currently sits at #64 in the Zacks Industry Rank. This group has gained an average of 3.46% so far this year, so GILD is performing better in this area.
Investors with an interest in Medical stocks should continue to track GILD. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on GILD - FREE